195 related articles for article (PubMed ID: 27181204)
1. The C/EBPδ protein is stabilized by estrogen receptor α activity, inhibits SNAI2 expression and associates with good prognosis in breast cancer.
Mendoza-Villanueva D; Balamurugan K; Ali HR; Kim SR; Sharan S; Johnson RC; Merchant AS; Caldas C; Landberg G; Sterneck E
Oncogene; 2016 Dec; 35(48):6166-6176. PubMed ID: 27181204
[TBL] [Abstract][Full Text] [Related]
2. C/EBPδ links IL-6 and HIF-1 signaling to promote breast cancer stem cell-associated phenotypes.
Balamurugan K; Mendoza-Villanueva D; Sharan S; Summers GH; Dobrolecki LE; Lewis MT; Sterneck E
Oncogene; 2019 May; 38(20):3765-3780. PubMed ID: 30262865
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPδ expression and contributes to transformation of breast tumor cells.
Sarkar TR; Sharan S; Wang J; Pawar SA; Cantwell CA; Johnson PF; Morrison DK; Wang JM; Sterneck E
Mol Cell Biol; 2012 Jan; 32(2):320-32. PubMed ID: 22037769
[TBL] [Abstract][Full Text] [Related]
4. The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis.
Balamurugan K; Wang JM; Tsai HH; Sharan S; Anver M; Leighty R; Sterneck E
EMBO J; 2010 Dec; 29(24):4106-17. PubMed ID: 21076392
[TBL] [Abstract][Full Text] [Related]
5. CCAAT/Enhancer binding protein delta (c/EBPdelta) regulation and expression in human mammary epithelial cells: I. "Loss of function" alterations in the c/EBPdelta growth inhibitory pathway in breast cancer cell lines.
Sivko GS; DeWille JW
J Cell Biochem; 2004 Nov; 93(4):830-43. PubMed ID: 15389879
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylation reduces C/EBPdelta (CEBPD) gene expression in the SUM-52PE human breast cancer cell line and in primary breast tumors.
Tang D; Sivko GS; DeWille JW
Breast Cancer Res Treat; 2006 Jan; 95(2):161-70. PubMed ID: 16322893
[TBL] [Abstract][Full Text] [Related]
7. CCAAT/enhancer binding protein delta (C/EBPδ) demonstrates a dichotomous role in tumour initiation and promotion of epithelial carcinoma.
Sowamber R; Chehade R; Bitar M; Dodds LV; Milea A; Slomovitz B; Shaw PA; George SHL
EBioMedicine; 2019 Jun; 44():261-274. PubMed ID: 31078521
[TBL] [Abstract][Full Text] [Related]
8. FBXW7α attenuates inflammatory signalling by downregulating C/EBPδ and its target gene Tlr4.
Balamurugan K; Sharan S; Klarmann KD; Zhang Y; Coppola V; Summers GH; Roger T; Morrison DK; Keller JR; Sterneck E
Nat Commun; 2013; 4():1662. PubMed ID: 23575666
[TBL] [Abstract][Full Text] [Related]
9. C/EBP{delta} targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression.
Pawar SA; Sarkar TR; Balamurugan K; Sharan S; Wang J; Zhang Y; Dowdy SF; Huang AM; Sterneck E
Proc Natl Acad Sci U S A; 2010 May; 107(20):9210-5. PubMed ID: 20439707
[TBL] [Abstract][Full Text] [Related]
10. PERK signaling through C/EBPδ contributes to ER stress-induced expression of immunomodulatory and tumor promoting chemokines by cancer cells.
Sheshadri N; Poria DK; Sharan S; Hu Y; Yan C; Koparde VN; Balamurugan K; Sterneck E
Cell Death Dis; 2021 Nov; 12(11):1038. PubMed ID: 34725321
[TBL] [Abstract][Full Text] [Related]
11. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2.
Chimge NO; Baniwal SK; Little GH; Chen YB; Kahn M; Tripathy D; Borok Z; Frenkel B
Breast Cancer Res; 2011; 13(6):R127. PubMed ID: 22151997
[TBL] [Abstract][Full Text] [Related]
12. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
13. CCAAT/Enhancer binding protein delta (c/EBPdelta) regulation and expression in human mammary epithelial cells: II. Analysis of activating signal transduction pathways, transcriptional, post-transcriptional, and post-translational control.
Sivko GS; Sanford DC; Dearth LD; Tang D; DeWille JW
J Cell Biochem; 2004 Nov; 93(4):844-56. PubMed ID: 15389878
[TBL] [Abstract][Full Text] [Related]
14. Expression of the CCAAT/enhancer-binding proteins C/EBPalpha, C/EBPbeta and C/EBPdelta in breast cancer: correlations with clinicopathologic parameters and cell-cycle regulatory proteins.
Milde-Langosch K; Löning T; Bamberger AM
Breast Cancer Res Treat; 2003 May; 79(2):175-85. PubMed ID: 12825852
[TBL] [Abstract][Full Text] [Related]
15. C/EBPδ: friend or foe? a novel role for C/EBPδ in metastasis.
Pelorosso FG; Balmain A
EMBO J; 2010 Dec; 29(24):4063-5. PubMed ID: 21157479
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
17. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells.
Ikezoe T; Gery S; Yin D; O'Kelly J; Binderup L; Lemp N; Taguchi H; Koeffler HP
Cancer Res; 2005 Jun; 65(11):4762-8. PubMed ID: 15930295
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor-α-miR-1271-SNAI2 feedback loop regulates transforming growth factor-β-induced breast cancer progression.
Liu BW; Yu ZH; Chen AX; Chi JR; Ge J; Yu Y; Cao XC
J Exp Clin Cancer Res; 2019 Mar; 38(1):109. PubMed ID: 30823890
[TBL] [Abstract][Full Text] [Related]
19. Interactions between CCAAT enhancer binding protein delta and estrogen receptor alpha control insulin-like growth factor I (igf1) and estrogen receptor-dependent gene expression in osteoblasts.
Chang W; Parra M; Centrella M; McCarthy TL
Gene; 2005 Jan; 345(2):225-35. PubMed ID: 15716114
[TBL] [Abstract][Full Text] [Related]
20. C/EBPδ-Slug-Lox1 axis promotes metastasis of lung adenocarcinoma via oxLDL uptake.
Wang D; Cheng X; Li Y; Guo M; Zhao W; Qiu J; Zheng Y; Meng M; Ping X; Chen X; Wang S; Luo J; Luo Q; Ma X; Xu L
Oncogene; 2020 Jan; 39(4):833-848. PubMed ID: 31562393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
